9 weeks that matter for patients with gastric cancer
Mené sur 507 patients atteints d'un cancer de l'estomac de stade avancé non résécable, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité d'un traitement à base de trifluridine et de tipiracil, après l'échec de plusieurs lignes thérapeutiques
Unresectable advanced or metastatic gastric cancer remains a difficult-to-manage disease, with poor median overall survival associated with first-line and second-line palliative systemic treatment. Therefore, there is an urgent need to further improve survival and to provide additional therapeutic options to patients who do not respond to or do not tolerate first-line and second-line chemotherapy regimens.
The Lancet Oncology , commentaire, 2017